EPIDEMIOLOGICAL, CLINICAL AND HUMANISTIC BURDEN AMONG ALK plus NON-SMALL CELL LUNG CANCER (ALK plus NSCLC) PATIENTS TREATED WITH FIRST-LINE ALK INHIBITORS: RESULTS OF A SYSTEMATIC LITERATURE REVIEW (SLR)

被引：0
|
作者：
Pan, X. [1 ]
Kwon, C. S. [2 ]
Garib, S. A. [2 ]
Forsythe, A. [2 ]
Lin, H. M. [1 ]
机构：
[1] Millennium Pharmaceut Inc, Cambridge, MA USA
[2] Purple Squirrel Econ, New York, NY USA
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
10.1016/j.jval.2019.04.127
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN3
引用
收藏
页码：S56 / S56
页数：1
相关论文
共 50 条
  • [1] BURDEN OF BRAIN METASTASES (BM) IN ALK plus NON-SMALL CELL LUNG CANCER (ALK plus NSCLC) TREATED WITH FIRST-LINE ALK INHIBITORS: RESULTS OF A SYSTEMATIC LITERATURE REVIEW (SLR)
    Pan, X.
    Kwon, C. S.
    Garib, S. A.
    Forsythe, A.
    Lin, H. M.
    VALUE IN HEALTH, 2019, 22 : S439 - S439
  • [2] Sequencing of ALK Inhibitors in ALK plus Non-Small Cell Lung Cancer
    Gadgeel, Shirish M.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2017, 18 (06)
  • [3] Outcomes of ALK plus non-small cell lung cancer (NSCLC) patients treated with ALK inhibitors in the clinical trial setting and in a referral Institution.
    Rojo, Ana Matres
    Felip, Enriqueta
    Dienstmann, Rodrigo
    Garces, Victor Navarro
    Viaplana, Cristina
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] SYSTEMATIC LITERATURE REVIEW (SLR) OF SEQUENCING OF ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS IN ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
    Barrows, S. M.
    Wright, K.
    Copley-Merriman, C.
    Kaye, J. A.
    Chioda, M. D.
    Wiltshire, R.
    Torgersen, K. M.
    Masters, E. T.
    VALUE IN HEALTH, 2018, 21 : S49 - S50
  • [5] Economic burden in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), with or without brain metastases, receiving first-line ALK inhibitors
    Wu, Yanyu
    Ren, Kaili
    Wan, Yin
    Lin, Huamao M.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (06) : 1418 - 1427
  • [6] DURATION OF TREATMENT AND ECONOMIC BURDEN IN PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE POSITIVE (ALK plus ) NON-SMALL CELL LUNG CANCER (NSCLC) RECEIVING SECOND-LINE ALK INHIBITORS
    Lin, H. M.
    Hou, P.
    Huang, H.
    Desai, A.
    Jahanzeb, M.
    VALUE IN HEALTH, 2018, 21 : S17 - S17
  • [7] Indirect Naive Comparison of ALK Inhibitors for ALK plus Non-Small Cell Lung Cancer (NSCLC) Post-Crizotinib Failure
    Reckamp, Karen L.
    Huang, Joice
    Huang, Hui
    Moore, Yan
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S313 - S314
  • [8] Optimal first-line treatment for metastatic ALK plus non-small cell lung cancer-a narrative review
    Chazan, Grace
    Solomon, Benjamin J.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (02) : 369 - 378
  • [9] Retrospective analysis of clinical outcomes of early stage ALK-positive (ALK plus ) non-small cell lung cancer (NSCLC).
    Dagogo-Jack, Ibiayi
    Santini, Fernando
    Eng, Juliana
    Yeap, Beow Y.
    Izar, Benjamin
    Chin, Emily
    Litvak, Anya
    Jones, David Randolph
    Kris, Mark G.
    Shaw, Alice Tsang
    Gainor, Justin F.
    Chaft, Jamie E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] AN ECONOMIC SYSTEMATIC LITERATURE REVIEW (SLR) FOR ANAPLASTIC LYMPHOMA KINASE-POSITIVE (ALK plus ) NON-SMALL-CELL LUNG CANCER (NSCLC)
    Robson, R. E.
    Cranmer, H.
    Huang, J.
    Selby, R.
    Lin, H. M.
    Tolley, K.
    VALUE IN HEALTH, 2018, 21 : S47 - S47
12345